Speedel Reports Successful SPP635 Phase IIa Trial in Hypertension
...veral new proprietary renin inhibitors invented by speedel Experimenta, the company's late-stage research uni...Medicine at the University of Lausanne, and acting speedel Medical Director, commented: "These positive resul...odels and human microdosing. In December 2001, speedel acquired a worldwide exclusive license from Roche ...Mergent, Inc. Announces Changes to the HealthShares(TM) European Drugs Index
...oday announced the following change effective on the opening of trading on Thursday August 14, 2008: Biotest AG (Frankfurt, Germany: BIO) will replace speedel Holding AG (SWX, Switzerland: SPPN) in the HealthShares(TM) European Drugs Index. Speedel Holding AG is being acquired by Novartis AG (SWX, Switzerlan...Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes
...AMO BIOSCIENCES INC. (NASDAQ: SGMO ) SCIELE PHARMA INC. (NASDAQ: SCRX ) speedel HOLDING AG-REG (SWX, Switzerland: SPPN) Add ABRAXIS BIOSCIENCE INC (NAS...HARMA (Oslo, Norway: PRON) Q-MED AB (OMX Nordic Exchange Stockholm: QMED) speedel HLDG AG (SWX, Switzerland: SPPN) STALLERGENES (Euronext, Paris: GENP) TRA...Anavex appoints Dr. Dimitri Goundis to lead Clinical Development
...nce in the management of clinical trials, including leadership positions at speedel AG (SWX: SPPN), The Medicines Company (NASDAQ: MDCO ) and Roche (SWX: ROG)...perimenta, the late-stage research unit of public biopharmaceutical company speedel AG. During his tenure, Dr. Goundis led the successful development of SPP100...